Nonetheless, given their functional relevance across key metabolic tissues and their regulatory roles throughout the spectrum of metabolic disease, both RKIP and YY1 represent viable and compelling targets for therapeutic intervention in obesity and T2D. Here, YY1 is linked to metabolic disease.